$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000165731222000027 Filed on August 09, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit	$0.00
YoY Change	-100.0%
Gross Profit Margin
Selling, General & Admin	$5.290M	$5.526M	$7.440M
YoY Change	-51.39%	-30.8%	-19.83%
% of Gross Profit
Research & Development	$9.838M	$14.98M	$17.63M
YoY Change	-56.39%	-27.14%	29.84%
% of Gross Profit
Depreciation & Amortization	$157.0K	$165.0K	$163.0K
YoY Change	-3.09%	6.45%	6.54%
% of Gross Profit
Operating Expenses	$15.13M	$20.51M	$25.07M
YoY Change	-54.76%	-28.16%	9.66%
Operating Profit	-$15.13M	-$20.51M	-$25.07M
YoY Change	-330.72%	-28.16%	9.66%
Interest Expense	$116.0K	$91.00K	$84.00K
YoY Change	34.88%	7.06%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$455.0K	$2.821M	$310.0K
YoY Change	-109.85%	-56.63%	-81.17%
Pretax Income	-$15.58M	-$17.69M	-$24.76M
YoY Change	-239.41%	-19.76%	16.71%
Income Tax	$64.00K	$79.00K	$82.00K
% Of Pretax Income
Net Earnings	-$15.65M	-$17.77M	-$24.84M
YoY Change	-241.59%	-19.49%	16.66%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03	-$0.04	-$0.05
Diluted Earnings Per Share	-$0.03	-$0.04	-$0.05
COMMON SHARES
Basic Shares Outstanding	487.6M shares	484.8M shares	481.9M shares
Diluted Shares Outstanding	544.1M shares	484.8M shares	481.9M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$231.7M	$111.5M	$132.8M
YoY Change	39.12%	-23.64%	-21.72%
Cash & Equivalents	$231.7M	$111.5M	$132.8M
Short-Term Investments
Other Short-Term Assets	$3.077M	$2.206M	$2.525M
YoY Change	361.32%	-4.91%	70.15%
Inventory
Prepaid Expenses	$3.355M	$4.731M	$1.246M
Receivables
Other Receivables
Total Short-Term Assets	$258.5M	$138.6M	$153.0M
YoY Change	40.09%	-35.9%	-18.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$81.00K	$91.00K	$71.00K
YoY Change	-7.95%	2.25%	-27.55%
Goodwill	$544.0K	$545.0K	$545.0K
YoY Change	-0.18%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$16.42M	$16.22M	$16.36M
YoY Change	-3.81%	631.14%	956.17%
TOTAL ASSETS
Total Short-Term Assets	$258.5M	$138.6M	$153.0M
Total Long-Term Assets	$16.42M	$16.22M	$16.36M
Total Assets	$274.9M	$154.9M	$169.3M
YoY Change	36.37%	-29.13%	-10.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.002M	$9.364M	$8.064M
YoY Change	88811.11%	27441.18%	1390.57%
Accrued Expenses	$22.98M	$28.60M	$28.88M
YoY Change	-13.15%	66.41%	239.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.13M	$38.86M	$37.90M
YoY Change	15.82%	-33.41%	198.5%
LONG-TERM LIABILITIES
Long-Term Debt	$5.000M	$5.000M	$4.900M
YoY Change	4.17%	4.17%	4.26%
Other Long-Term Liabilities	$224.0K	$132.0K	$177.0K
YoY Change	-71.89%	-86.45%	-55.75%
Total Long-Term Liabilities	$5.259M	$5.113M	$5.105M
YoY Change	-6.39%	-10.94%	1.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.13M	$38.86M	$37.90M
Total Long-Term Liabilities	$5.259M	$5.113M	$5.105M
Total Liabilities	$37.39M	$43.98M	$43.01M
YoY Change	12.08%	-31.4%	142.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$322.4M	-$306.7M	-$288.7M
YoY Change	34.17%	22.05%	26.4%
Common Stock	$39.12M	$32.18M	$32.18M
YoY Change	22.8%	1.12%	1.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$449.0K	$591.0K	$739.0K
YoY Change	-41.69%	-29.89%	-55.75%
Treasury Stock Shares
Shareholders Equity	$237.5M	$110.9M	$126.3M
YoY Change
Total Liabilities & Shareholders Equity	$274.9M	$154.9M	$169.3M
YoY Change	36.37%	-29.13%	-10.96%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$15.65M	-$17.77M	-$24.84M
YoY Change	-241.59%	-19.49%	16.66%
Depreciation, Depletion And Amortization	$157.0K	$165.0K	$163.0K
YoY Change	-3.09%	6.45%	6.54%
Cash From Operating Activities	-$18.10M	-$19.52M	-$14.51M
YoY Change	-179.28%	-3.41%	-21.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$29.00K	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	$0.00	-$29.00K	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$67.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	139.6M	-689.0K	-$726.0K
YoY Change	-7784.04%	-79.73%
NET CHANGE
Cash From Operating Activities	-18.10M	-19.52M	-$14.51M
Cash From Investing Activities	0.000	-29.00K	$0.00
Cash From Financing Activities	139.6M	-689.0K	-$726.0K
Net Change In Cash	121.5M	-20.24M	-$15.62M
YoY Change	478.77%	-14.28%	-15.08%
FREE CASH FLOW
Cash From Operating Activities	-$18.10M	-$19.52M	-$14.51M
Capital Expenditures	$0.00	-$29.00K	$0.00
Free Cash Flow	-$18.10M	-$19.49M	-$14.51M
YoY Change	-179.24%	-3.55%	-21.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38067
	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	44
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	283 4200
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
	dei	Trading Symbol TradingSymbol	VRNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	487633374	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111510000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148380000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4731000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	usd
CY2022Q2	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	20185000	usd
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2206000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2063000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	138632000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	170063000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	91000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	545000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	588000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899000	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	16224000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16524000	usd
CY2022Q2	us-gaap	Assets Assets	154856000	usd
CY2021Q4	us-gaap	Assets Assets	186587000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9364000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10044000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28603000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	464000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	648000	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	311000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	147000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	121000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	38863000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33422000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4981000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4874000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	132000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5113000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5160000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	43976000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	38582000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	494058246	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	485298326	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480082966	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	32182000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31855000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	390543000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385070000	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	591000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	603000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306653000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263716000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	110880000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	154856000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186587000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14982000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20563000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32607000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34137000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5526000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7985000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12966000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17267000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	20508000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	28548000	usd
	us-gaap	Operating Expenses OperatingExpenses	45573000	usd
	us-gaap	Operating Expenses OperatingExpenses	51404000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20508000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-28548000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45573000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51404000	usd
CY2022Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	5409000	usd
CY2021Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	3836000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	6711000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	5906000	usd
CY2022Q2	us-gaap	Investment Income Net InvestmentIncomeNet	165000	usd
CY2021Q2	us-gaap	Investment Income Net InvestmentIncomeNet	3000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	180000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	7000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	91000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	85000	usd
	us-gaap	Interest Expense InterestExpense	175000	usd
	us-gaap	Interest Expense InterestExpense	169000	usd
CY2022Q2	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	usd
CY2021Q2	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2711000	usd
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	usd
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2204000	usd
CY2022Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-2662000	usd
CY2021Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	40000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-3585000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	203000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2821000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6505000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3131000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8151000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17687000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22043000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42442000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43253000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	79000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	161000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	105000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-17766000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42603000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	484777837	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	484777837	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	470786767	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	470786767	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	483226039	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483226039	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469036978	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	793000	usd
CY2022Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-118000	usd
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	80696	shares
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-17766000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	689000	usd
CY2022Q2	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	25000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3053000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	110880000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	383000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7450000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	154397000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42603000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3256000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	186000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	69000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2204000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6801000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	16300000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	328000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	305000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25002000	usd
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	usd
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	694000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5279000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	6461000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	5848000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	143000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	600000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6325000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-338000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4823000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-680000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-144000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6347000	usd
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	393000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	164000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40051000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-113000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	182000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34029000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38756000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1482000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	383000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1415000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3399000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1397000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36870000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41951000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111510000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146035000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	115000	usd
	us-gaap	Interest Paid Net InterestPaidNet	109000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306700000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	100000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2022Q2	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	20185000	usd
CY2021Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15583000	usd
CY2022Q2	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	20185000	usd
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	usd
CY2022Q2	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	26364000	usd
CY2021Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	21336000	usd
CY2022Q2	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1093000	usd
CY2021Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	919000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1146000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28603000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5000000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3053000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7451000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6801000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16300000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	608000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.62
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13303200	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.34
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42603000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-43358000	usd
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46183144	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1760000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15063200	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2022Q2	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-17766000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	484777837	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	484777837	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	470786767	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	470786767	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	483226039	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483226039	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469036978	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469036978	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46183144	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75713291	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75713291	shares
CY2022Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	1300000	usd

Files In Submission

Name	View Source	Status
0001657312-22-000027-index-headers.html	Edgar Link	pending
0001657312-22-000027-index.html	Edgar Link	pending
0001657312-22-000027.txt	Edgar Link	pending
0001657312-22-000027-xbrl.zip	Edgar Link	pending
exhibit311q222.htm	Edgar Link	pending
exhibit312q222.htm	Edgar Link	pending
exhibit321q222.htm	Edgar Link	pending
exhibit322q222.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20220630.htm	Edgar Link	pending
vrna-20220630.xsd	Edgar Link	pending
vrna-20220630_def.xml	Edgar Link	unprocessable
vrna-20220630_pre.xml	Edgar Link	unprocessable
vrna-20220630_lab.xml	Edgar Link	unprocessable
vrna-20220630_htm.xml	Edgar Link	completed
vrna-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2022 Q3 Form 10-Q Financial Statement

#000165731222000027 Filed on August 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2022 Q3 Form 10-Q Financial Statement

#000165731222000027 Filed on August 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna